Name: Biogen Inc. (NASDAQ:BIIB) | Analysis of Revenues
Creator: Stock Analysis on Net

Analysis of Revenues

Biogen Inc., income statement, revenues

US$ in thousands

12 months ended:	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Multiple Sclerosis (MS)	6,096,700)	7,832,100)	8,529,300)	8,595,200)	8,977,200)
Spinal Muscular Atrophy	1,905,100)	2,052,100)	2,097,000)	1,724,200)	883,700)
Alzheimer’s disease	3,000)	—)	—)	—)	—)
Biosimilars	831,100)	795,800)	738,300)	545,100)	379,800)
Other	11,000)	12,200)	15,200)	22,300)	39,600)
Hemophilia	—)	—)	—)	—)	74,400)
Product revenues	8,846,900)	10,692,200)	11,379,800)	10,886,800)	10,354,700)

Download chart

Item	Description	The company
Product revenues	Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).	Biogen Inc. product revenues decreased from 2019 to 2020 and from 2020 to 2021.